PTC Therapeutics Inc PTCT

NAS: PTCT | ISIN: US69366J2006 15/10/2026

60,99 USD (+2,21%)

(+2,21%) 15/10/2026

Grafiek PTC Therapeutics Inc

Grafiek PTC Therapeutics Inc

1 dag1d 2,21%
1 week1w -5,73%
1 maand1m -9,76%
3 maanden3m -22,33%
6 maanden6m -14,94%
1 jaar1j -8,72%
5 jaar5j 63,21%

PTC Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

15 oktober 2026 · PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026 · Persbericht

25 september 2026 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

21 september 2026 · PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy · Persbericht

27 augustus 2026 · PTC Therapeutics to Participate in Upcoming Investor Conferences · Persbericht

24 augustus 2026 · PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile · Persbericht

12 augustus 2026 · PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program · Persbericht

30 juli 2026 · PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results · Persbericht

23 juli 2026 · Hamilton Lane Board Elects Michael Schmertzler as New Independent Director · Persbericht

16 juli 2026 · PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026 · Persbericht

17 juni 2026 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Profiel PTC Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.ptcbio.com

Hoofdzetel: South Plainfield, New Jersey Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe